MLR Review Software Problems: The 7 That Cost Real Money, and How to Avoid Them

Why does an MLR build get scoped as a document workflow when the risk lives in claims?

Nearly every failed promotional review project we have seen started with the same scoping conversation. Someone described the current process, which is a file moving between a medical reviewer, a legal reviewer and a regulatory reviewer, and the developer built exactly that. The result is a workflow engine around a document, which is what Veeva Vault PromoMats and Vodori Pepper Flow already do, only slower and without their annotation maturity.

This is specific to pharmaceutical commercial operations because the unit that carries liability is not the file. It is the claim: a statement about the product, tied to a reference, approved for an indication, in a market, for a period. The same sentence lives in forty assets in forty slightly different wordings, and when the substantiation moves, nobody can produce the list of live material affected. A workflow engine cannot answer that question because it never stored the relationship.

The fix is a data model decision made before any screen is designed. The claim becomes the primary record with its own version history, its own linked references and its own status per market and per indication. An asset becomes a composition of placements, each bound to a specific claim version. Once that exists, reviewers open a file where eight of ten placements are already approved claim versions and only two need fresh reading, and a reference change produces an exact impact list instead of a search. If a prospective developer draws documents and approvals on the whiteboard, they have quoted the wrong system.

What goes wrong when you migrate an approved asset library?

The second reliable failure is migration. A company decides to bring five years of approved assets into the new system so nothing is lost, and the project stalls for months. The reason is that legacy assets have no claim bindings. They were approved as documents, so the claim data your new model requires simply does not exist in the source, and reconstructing it means someone reading each asset and deciding which claim version each sentence corresponds to.

Teams try three shortcuts and all three cost more than they save. Importing assets without bindings gives you a library that looks complete and cannot participate in a withdrawal cascade, which is the exact capability you paid for. Fuzzy text matching produces bindings nobody trusts, and an untrusted binding in a regulated system is worse than none. Re reviewing everything triples the medical and regulatory workload while the team is still learning new software.

The approach that works is unglamorous. Migrate the canonical claim set first, agreed between medical and regulatory as the wording that is actually approved today. Bind only assets that are still in market and still within their expiry, which is typically a fraction of the archive. Import everything else as a read only historical record with its original approval evidence attached, marked explicitly as unbound and out of scope for withdrawal. Companies that migrate every brand and every archived asset at once spend the first quarter in data cleanup and lose the momentum that funds the second phase.

Why do the distribution integrations break after launch?

Withdrawal only works if the system can reach the places material actually lives, which means a customer relationship management (CRM) library on rep devices, a product website, an email platform, a congress or event portal and printed inventory in a warehouse. Each of those is a separate integration with a separate failure mode, and the failures share a pattern: they are silent.

A rep tablet syncs on a schedule and only when the device is online, so an unpublish issued on Thursday may not take effect on a device that has been in a bag since Tuesday. A content management system accepts the API call and returns success while a cache layer keeps serving the old page. An email platform disables a template while a scheduled send already holds a rendered copy. Printed inventory has no API at all, so the withdrawal is a task assigned to a human in a warehouse, and if nobody closes it the record says pending forever.

The design that survives launch treats each endpoint as an adapter with three obligations: issue the instruction, verify the resulting state by reading it back, and record a completion event with a timestamp and the identity of whoever or whatever confirmed it. Devices that have not synced within the expected window appear on an exception list with the assigned representative named. Physical destruction produces a signed record. What you want at the end is one screen showing what is invalid, where it still exists and who owes you an action, which turns an inspection question into a short answer rather than a reconstruction.

What happens when expiry driven withdrawal is not covered in phase one?

Withdrawal is routinely deferred because it looks like a phase two feature. It is not. It is the reason the claim model exists, and deferring it means the first release is a review queue that duplicates what you already own.

The operational gap is easy to describe. Your review platform sets an expiry date on an asset and emails the owner when it approaches. That handles the predictable case where an asset simply ages out. It does not handle the case that actually hurts, which is a reference changing mid cycle, because the trigger is not a date. A label update, a narrowed indication or a retracted study invalidates claims immediately, and every asset resting on those claims becomes a problem the same afternoon.

The compliance consequence compounds. Form FDA 2253 submission at first use is a packet assembly exercise that most companies do by hand, and the same missing relationships that block withdrawal also make packet assembly manual. When the claim, the reference, the approval evidence and the distribution record are one connected structure, the packet generates. When they are folders, someone rebuilds it. Build the cascade in the first release even if you only wire one endpoint, because a cascade with one working adapter proves the model and a cascade specified for later usually never arrives.

Should you build custom or configure what you already own?

Configure, genuinely, if you are a single brand company in one market with a review committee that fits around one table and a few hundred assets a year. Veeva Vault PromoMats is the category default for good reasons: the annotation is mature, the audit trail is serious and the expiry and approval mechanics are correct for that shape of business. Vodori Pepper Flow is a lighter and faster option at smaller scale and is often the better buy for a company that finds Vault heavy. Aprimo comes from marketing resource management and is stronger on planning than on claim level substantiation, and Ennov is document centric in the same way Vault is. At single brand scale a custom build is a distraction from launch and we would tell you so.

Before you commission anything, spend two weeks pushing your existing platform harder. Most companies have never defined a canonical claim list, and have not asked what their platform can do with distribution endpoints. Some of what looks like a product limit is a configuration gap.

Build when the claim really is your unit of risk. The signals are consistent: the same statements recur across brands and channels, you operate in more than three markets with genuinely different review chains, your assets are majority video and interactive rather than page based, your last reference change triggered a sweep that took more than a day, and your agencies and affiliates sit outside the system because seat cost pushed them into email.

How do hidden costs get into the quote?

A first release covering the claims register, reference linking, asset composition, routed review with annotation and an audit trail runs $90,000 to $180,000 and ships in 14 to 20 weeks in Digital Heroes delivery experience. A full platform adding video and interactive annotation, affiliate review chains, withdrawal to live endpoints and 2253 packet assembly runs $250,000 to $600,000 phased over 8 to 14 months. The overruns come from five places, and all five are visible before kickoff if you look.

• Market count. Each affiliate chain is a distinct rule set with its own reviewer roles, its own mandatory local text and sometimes a national association pre vetting step. Quotes priced for one market and delivered for five are the most common overrun in this category.
• Endpoint count. Four distribution channels is four integrations with four verification problems, not one line item called distribution.
• Interactive and video annotation. Anchoring a comment to a timecode or a named module state is genuinely harder engineering than annotating a page, and many quotes quietly assume flattened screenshots.
• Library migration. Priced as data loading, delivered as claim reconstruction by medical and regulatory staff whose time was never in the budget.
• Validation expectations. If your quality organisation treats the system as relevant to good practice regulations, qualification documentation is real effort and it belongs in the plan rather than in a surprise.

What separates a build that works from one that fails here?

Four things, and none of them are technology choices. The first is that medical and regulatory agree the canonical claim set before engineering starts. That agreement is a content exercise, it takes longer than anyone expects because the same claim exists in several approved wordings, and projects that expect the software to produce the list instead of consume it lose a month.

The second is that the first release wires at least one real withdrawal endpoint end to end. A cascade that stops at a notification has not been proven, and proving it on one channel tells you more than specifying it for six.

The third is that external contributors are inside the system from day one. Agencies, medical writers, congress vendors and affiliate marketers should get scoped, time limited access to the specific assets they work on, with no licence economics forcing them back into email. The measurable effect is that the review clock starts when the agency uploads rather than when someone opens an attachment, and that single change usually shortens cycle time more than any workflow refinement.

The fourth is ownership. You should hold the repository, the cloud accounts and the unrestricted right to hire another firm, written into the contract before kickoff. At Digital Heroes the client owns the code from the first commit. Promotional approval evidence has to be producible years after a campaign ends, and evidence that sits inside a vendor relationship you might want to leave is a continuity risk as well as a commercial one.